Vaptans
Abstract
This is ashort and Comprehensive review of vaptansReferences
References
1 . Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science.1991;252:572–574.
2 Peri A. A. Clinical review: the use of vaptans in clinical endocrinology. J Clin
Endocrinol Metab. 2013 Apr;98(4):1321-32
3 Schrier RW, Gross P, Gheorghiade M, et al Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099.
4. Berl T, Quittnat-Pelletier F, Verbalis JG, Oral tolvaptan is safe and effective in chronic hyponatremia J Am Soc Nephrol. 2010;21(4):705.
5 Higashihara E, Torres VE, Chapman AB, Grantham JJ,et al Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507
6 Torres VE, Chapman AB, Devuyst O,et al, Tolvaptan in patients with autosomal dominant polycystic kidney disease, N Engl J Med. 2012;367(25):2407.
7. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf). 2008;69:159–168
8 Abraham WT, Decaux G, Josiassen RC, et al, Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia ,Kidney Int. 2012 Dec;82(11):1215-22
9 Abraham WT, Hensen J, Gross PA et al, Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia, Kidney Int. 2012 Dec;82(11):1223-30.
1 . Yamamura Y, Ogawa H, Chihara T, et al. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science.1991;252:572–574.
2 Peri A. A. Clinical review: the use of vaptans in clinical endocrinology. J Clin
Endocrinol Metab. 2013 Apr;98(4):1321-32
3 Schrier RW, Gross P, Gheorghiade M, et al Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med. 2006;355(20):2099.
4. Berl T, Quittnat-Pelletier F, Verbalis JG, Oral tolvaptan is safe and effective in chronic hyponatremia J Am Soc Nephrol. 2010;21(4):705.
5 Higashihara E, Torres VE, Chapman AB, Grantham JJ,et al Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience Clin J Am Soc Nephrol. 2011 Oct;6(10):2499-507
6 Torres VE, Chapman AB, Devuyst O,et al, Tolvaptan in patients with autosomal dominant polycystic kidney disease, N Engl J Med. 2012;367(25):2407.
7. Verbalis JG, Zeltser D, Smith N, Barve A, Andoh M. Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study. Clin Endocrinol (Oxf). 2008;69:159–168
8 Abraham WT, Decaux G, Josiassen RC, et al, Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia ,Kidney Int. 2012 Dec;82(11):1215-22
9 Abraham WT, Hensen J, Gross PA et al, Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia, Kidney Int. 2012 Dec;82(11):1223-30.
Published
2015-10-01
How to Cite
GOPAL, Raju A.
Vaptans.
BMH Medical Journal - ISSN 2348–392X, [S.l.], v. 2, n. 4, p. 106-109, oct. 2015.
ISSN 2348-392X.
Available at: <https://www.babymhospital.org/BMH_MJ/index.php/BMHMJ/article/view/69>. Date accessed: 09 may 2024.
Section
Review Articles
